US Stock MarketDetailed Quotes

NVCT Nuvectis Pharma

Watchlist
  • 6.550
  • +0.130+2.02%
Close Jan 24 16:00 ET
126.55MMarket Cap-5.65P/E (TTM)

About Nuvectis Pharma Company

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Company Profile

SymbolNVCT
Company NameNuvectis Pharma
Listing DateFeb 4, 2022
Issue Price5.00
Founded2020
CEOMr. Ron Bentsur
MarketNASDAQ
Employees13
Fiscal Year Ends12-31
Address1 Bridge Plaza,Suite 275,2nd floor
CityFort Lee
ProvinceNew Jersey
CountryUnited States of America
Zip Code07024
Phone1-201-614-3151
Websitehttp://nuvectis.com

Company Executives

  • Name
  • Position
  • Salary
  • Ron Bentsur
  • Chairman of the Board, Chief Executive Officer and President
  • 2.69M
  • Shay Shemesh
  • Executive Vice President, Chief Development and Operations Officer
  • 1.56M
  • Enrique Poradosu
  • Executive Vice President, Chief Scientific and Business Officer
  • 1.56M
  • Michael J. Carson
  • Vice President of Finance, Principal Financial and Accounting Officer
  • --
  • Matthew L. Kaplan
  • Independent Director
  • 375.80K
  • Kenneth Hoberman
  • Independent Director
  • 385.80K
  • James F. Oliviero, III
  • Independent Director
  • 385.80K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
GVS
870976
+29.98%
Hangzhou CNCR-IT
300250
+20.03%
Shanghai Newtouch Software
688590
+20.01%
4
Ucap Cloud Information Technology Co.,Ltd
688228
+20.00%
5
Yangtze Optical Electronic
688143
+20.00%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
January rate meeting coming! Fed's pause in rate cuts a foregone conclusion?
🎙️Discussion 1. Will the Fed press the "pause button" on rate cuts as expected? 2. Do you think President Trump's political actions will ch Show More
Here's the Breakdown for December CPI, in One Chart
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.